Edesa Biotech has turned into a tale of two timelines: a stock that has more than doubled in a month, yet is now giving back ground, while the short sellers who built up against it have beaten a rapid retreat.
The price move sets the scene. EDSA closed Friday at $16.30, down 7.3% on the week and 6.5% in Friday's session alone. That pullback follows a staggering 169% gain over the prior month — a run that squeezed out a large chunk of the short position and left the stock vulnerable to profit-taking once momentum faded.
The short covering tells that story clearly. Short interest has collapsed by 52% in one week, falling to roughly 165,900 shares and 2.4% of the free float. A month ago, that figure was closer to 6.3% of float. The speed of the unwind points to a classic squeeze dynamic: a small-cap biotech with a thin float, a meaningful short base, and a catalyst-driven price spike that forced bears to cover in size. What's left is a much lighter short book. Days to cover, per FINRA's fortnightly data, is just one day — there is no longer a structural overhang from shorts needing time to exit.
The borrow market tells a more nuanced story. Despite the short interest retreat, the cost to borrow remains extraordinarily elevated at 242% annualised — down about 14% on the week but still near the top of its 30-day range. Availability is tight at 58% of short interest, meaning the lending pool is far from loose. That combination — expensive borrow, constrained availability — reflects a market where shares remain genuinely hard to source, even as the outstanding short position has shrunk. Availability has not recovered to comfortable levels; it touched 100% utilisation as recently as April 29-30 when the squeeze was at its most acute, and the lending market has only partially normalised since.
The Street picture is sparse and warrants a clear caveat. HC Wainwright is the sole covering firm, maintaining a Buy rating. Its most recent published price target of $5 — last reiterated in November 2025 — looks badly out of step with the current $16.30 price. An older HC Wainwright target of $21 dates to early 2025 and predates what appear to have been significant corporate developments. Neither figure should be treated as current guidance; the analyst data here is stale and the gap between $5 and $16 strongly suggests the target has not caught up with the stock's move. An enterprise value in the vicinity of $48 million (per the most recent filing) looks modest relative to where the stock now trades, though for a pre-revenue clinical-stage biotech, traditional valuation anchors carry limited weight.
The institutional register offers one genuinely interesting detail. Point72 Asset Management disclosed a fresh position of 600,000 shares as of early March, and Perceptive Advisors — a specialist healthcare fund — initiated with 563,239 shares around the same time. Together those two new entrants account for over 13% of shares outstanding. CEO Pardeep Nijhawan, listed as the third-largest holder with 6.15% of shares, was an active open-market buyer through early March, accumulating around 34,000 shares at prices ranging from $2 to $6.60. That buying came before the big rally. His total reported net position over the past 90 days runs to roughly 109,000 shares net, weighted heavily by equity awards alongside the cash purchases.
The most recent earnings release was May 8 — yesterday relative to this note — but no price-reaction data is yet attached to that event. The two prior prints produced divergent moves: a one-day drop of 12% followed by a five-day recovery of 33% in February, and a modest 3% gain with a 20% five-day reversal a few sessions earlier. The pattern suggests the stock can swing hard in both directions around results, with multi-day moves sometimes disconnecting from the initial reaction.
What to watch now is whether the post-squeeze borrow conditions ease further — if availability loosens and cost to borrow retreats toward more normal levels, it removes one of the structural supports that compressed short sellers during the rally — and how the market responds once the May 8 earnings details are digested.
See the live data behind this article on ORTEX.
Open EDSA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
